Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Polidocanol
Drug ID BADD_D01792
Description Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Indications and Usage Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
Marketing Status Prescription
ATC Code C05BB02
DrugBank ID DB06811
KEGG ID D01993
MeSH ID D000077423
PubChem ID 656641
TTD Drug ID D05ZPL
NDC Product Code 52919-021; 60635-107; 67850-141; 67850-140; 60635-118; 60635-111; 52919-024; 52919-022; 46783-221; 46783-121; 72969-060; 60635-133
Synonyms Polidocanol | Polidocanols | Laureth 9 | Laureth-9 | Lubrol 12A9 | Laureth-7 | Laureth 7 | Polyethylene Glycol-7-lauryl Ether | Ether, Polyethylene Glycol-7-lauryl | Polyethylene Glycol 7 lauryl Ether | Polyethylene Glycol-7-lauryl Ethers | Lauromacrogol | Lauromacrogols | Polyoxyethylene Lauryl Ether | Ether, Polyoxyethylene Lauryl | Polyoxyethylene Lauryl Ethers | Thesit | Nonaethylene Glycol Monododecyl Ether | Nonaethyleneglycol Monododecyl Ether | Ether, Nonaethyleneglycol Monododecyl | Monododecyl Ether, Nonaethyleneglycol | Nonaethyleneglycol Monododecyl Ethers | alpha-Dodecyl-omega-hydroxypoly(oxy-1,2ethanediyl) | Polyoxyethylene-4-dodecyl Ether | Ether, Polyoxyethylene-4-dodecyl | Polyoxyethylene 4 dodecyl Ether | Polyoxyethylenedodecyl Ether | Polyoxyethylenedodecyl Ethers | Tetraethyleneglycol Lauryl Ether | Ether, Tetraethyleneglycol Lauryl | Lauryl Ether, Tetraethyleneglycol | Tetraethyleneglycol Lauryl Ethers | Laureth-4 | Laureth 4 | Polyoxyethylene(4) Lauryl Ether | Lauromacrogol 400 | Polyethylene Glycol Monododecyl Ether | Brij 30 | Brij-30 | Brij30 | Tetraethylene Glycol Dodecyl Ether | Laureth | Laureths | Dodecyl Ethyleneglycol Monoether | Dodecyl Ethyleneglycol Monoethers | Ethyleneglycol Monoether, Dodecyl | Monoether, Dodecyl Ethyleneglycol | Laureth-1 | Laureth 1 | Aethoxysclerol | Ethoxysclerol | Aethoxysklerol | Atossisclerol | Atoxysclerol | Aetoxisclerol | Hydroxypolyethoxydodecane | Lubrol-PX | Lubrol PX | Polyoxyethylene 9-lauryl Ether | Ether, Polyoxyethylene 9-lauryl | Polyoxyethylene 9 lauryl Ether | Polyoxyethylene 9-lauryl Ethers
Chemical Information
Molecular Formula C30H62O10
CAS Registry Number 3055-99-0
SMILES CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal sensation in eye06.01.01.0010.000572%Not Available
Anaphylactic shock24.06.02.004; 10.01.07.0020.000572%Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Asthenia08.01.01.0010.001430%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Back pain15.03.04.0050.000572%
Blister23.03.01.001; 12.01.06.0020.001430%Not Available
Cardiac arrest02.03.04.001--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.001144%Not Available
Circulatory collapse24.06.02.001--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Dermatitis allergic23.03.04.003; 10.01.03.0140.000572%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.000572%
Dyspnoea22.02.01.004; 02.01.03.0020.000858%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000572%Not Available
Erythema23.03.06.0010.002573%Not Available
Extravasation08.01.03.0080.000572%Not Available
Eyelid oedema06.04.04.004; 23.04.01.003; 10.01.05.0010.000572%Not Available
Feeling abnormal08.01.09.0140.000858%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000572%
Headache17.14.01.0010.000858%
Hypersensitivity10.01.03.0030.000572%
Hypertrichosis23.02.04.002--
Hypokinesia17.01.02.0090.000858%Not Available
Hypotension24.06.03.0020.000572%
Injection site haematoma24.07.01.009; 12.07.03.004; 08.02.03.004--Not Available
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Injection site necrosis12.07.03.020; 08.02.03.020--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages